ABVX - Abivax S.A.


5.86
0.690   11.775%

Share volume: 439,755
Last Updated: 04-09-2025
Pharmaceutical Products/Pharmaceutical Preparations: 0.07%

PREVIOUS CLOSE
CHG
CHG%

$5.17
0.69
0.13%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
8%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 20%
Performance
5 Days
12.05%
1 Month
-8.86%
3 Months
-22.89%
6 Months
-22.89%
1 Year
-22.89%
2 Year
-22.89%
Key data
Stock price
$5.86
P/E Ratio 
N/A
DAY RANGE
$4.77 - $6.30
EPS 
N/A
52 WEEK RANGE
$4.77 - $8.47
52 WEEK CHANGE
-$22.89
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
0.000
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
09-08-2025
BETA 
0.00
PUBLIC FLOAT 
N/A
AVERAGE 10 VOLUME 
$232,259
AVERAGE 30 VOLUME 
$283,337
Company detail
CEO: Marc de Garidel
Region: US
Website: www.abivax.com
Employees: 0
IPO year: 2023
Issue type:
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

We are a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. We were incorporated as a société anonyme (limited liability company) on December 4, 2013 and registered at the Paris Trade and Company Register on December 27, 2013 for a period of 99 years until December 22, 2112, subject to extension or early dissolution, under the number 799 363 718. Our principal executive offices are located at 7-11 boulevard Haussmann 75009 Paris, France, and our telephone number is +33 (0) 1 53 83 08 41. We have one wholly owned subsidiary, Abivax LLC, a Delaware limited liability company, formed on March 20, 2023. Our agent for service of process in the United States is CT Corporation System, 1015 15th Street N.W., Suite 1000, Washington, D.C.

Recent news
loading